Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study

Harry J. M. Groen, Hannie Sietsma, Andrew Vincent, Monique M. H. Hochstenbag, John W. G. van Putten, Anke van den Berg, Otilia Dalesio, Bonne Biesma, Hans J. M. Smit, Arien Termeer, T. Jeroen N. Hiltermann, Ben E. E. M. van den Borne, Franz M. N. H. Schramel

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4320-4326
JournalJournal of Clinical Oncology
Volume29
Issue number32
DOIs
Publication statusPublished - 10 Nov 2011

Cite this

Groen, H. J. M., Sietsma, H., Vincent, A., Hochstenbag, M. M. H., van Putten, J. W. G., van den Berg, A., Dalesio, O., Biesma, B., Smit, H. J. M., Termeer, A., Hiltermann, T. J. N., van den Borne, B. E. E. M., & Schramel, F. M. N. H. (2011). Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study. Journal of Clinical Oncology, 29(32), 4320-4326. https://doi.org/10.1200/JCO.2011.35.5214